(Q40287703)

English

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

scientific article published on 7 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial (English)

1 reference

Europe PubMed Central

19 September 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

5

object named as

Kathrin U Jansen

1 reference

Europe PubMed Central

19 September 2017

Leszek Szenborn

9

object named as

Leszek Szenborn

1 reference

Europe PubMed Central

19 September 2017

10

object named as

Jacek Wysocki

1 reference

Europe PubMed Central

19 September 2017

author name string

Peter C Richmond

1

1 reference

Europe PubMed Central

19 September 2017

Helen S Marshall

2

1 reference

Europe PubMed Central

19 September 2017

Michael D Nissen

3

1 reference

Europe PubMed Central

19 September 2017

Qin Jiang

4

1 reference

Europe PubMed Central

19 September 2017

Maria Garcés-Sánchez

6

1 reference

Europe PubMed Central

19 September 2017

Federico Martinón-Torres

7

1 reference

Europe PubMed Central

19 September 2017

Johannes Beeslaar

8

1 reference

Europe PubMed Central

19 September 2017

Joseph Eiden

11

1 reference

Europe PubMed Central

19 September 2017

Shannon L Harris

12

1 reference

Europe PubMed Central

19 September 2017

Thomas R Jones

13

1 reference

Europe PubMed Central

19 September 2017

John L Perez

14

1 reference

Europe PubMed Central

19 September 2017

2001 Study Investigators

15

1 reference

Europe PubMed Central

19 September 2017

publication date

7 May 2012

1 reference

Europe PubMed Central

19 September 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

19 September 2017

12

1 reference

Europe PubMed Central

19 September 2017

8

1 reference

Europe PubMed Central

19 September 2017

597-607

1 reference

Europe PubMed Central

19 September 2017

Meningococcal carriage by age: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical recognition of meningococcal disease in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of vaccine research and development: meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quadrivalent meningococcal conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970087-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(12)70087-7

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40287703&oldid=1956514376"